“Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial”, J of Skin, vol. 8, no. 6, p. s490, Nov. 2024, doi: 10.25251/skin.8.supp.490.